Grant Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
	Jan. 13, 2022	Mar. 31, 2025	Dec. 31, 2025	Mar. 31, 2026
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrued and other liabilities			$ 83,012	$ 68,113
Restricted cash and cash equivalents, current		$ 88,151	1,922	1,925
Vaccinal Antibody Grant | Grant revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Other revenue		$ 1,200
Vaccinal Antibody Grant | Gates Foundation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares purchased (in shares)	881,365
Common stock, shares purchased price (in USD per share)	$ 45.38
Common stock, shares purchased, aggregate purchase price	$ 40,000
Common stock, shares issued, fair market value	$ 28,500
Closing stock price (in USD per share)	$ 37.65
Premium received	$ 11,300
Unrecognized premium				9,000
Unused grant funds returned			9,500
Accrued and other liabilities			$ 1,800	1,800
Restricted cash and cash equivalents, current				1,800
Vaccinal Antibody Grant | Gates Foundation | Accrued Liabilities and Other Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unrecognized premium				4,000
Vaccinal Antibody Grant | Gates Foundation | Other Noncurrent Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unrecognized premium				$ 5,000